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MaBACKGROUND There is a paucity of prospective and controlled data on the comparative effectiveness of transcatheter
aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in a real-world setting.
OBJECTIVES This analysis aims to describe 1-year clinical outcomes of a large series of propensity-matched patients
who underwent SAVR and transfemoral TAVR.
METHODS The OBSERVANT (Observational Study of Effectiveness of SAVR–TAVI Procedures for Severe Aortic
Stenosis Treatment) trial is an observational prospective multicenter cohort study that enrolled patients with aortic
stenosis (AS) who underwent SAVR or TAVR. The propensity score method was applied to select 2 groups with
similar baseline characteristics. All outcomes were adjudicated through a linkage with administrative databases.
The primary endpoints of this analysis were death from any cause and major adverse cardiac and cerebrovascular
events (MACCE) at 1 year.
RESULTS The unadjusted enrolled population (N ¼ 7,618) included 5,707 SAVR patients and 1,911 TAVR patients.
The matched population had a total of 1,300 patients (650 per group). The propensity score method generated a
low-intermediate risk population (mean logistic EuroSCORE 1: 10.2  9.2% vs. 9.5  7.1%, SAVR vs. transfemoral
TAVR; p ¼ 0.104). At 1 year, the rate of death from any cause was 13.6% in the surgical group and 13.8% in the
transcatheter group (hazard ratio [HR]: 0.99; 95% conﬁdence interval [CI]: 0.72 to 1.35; p ¼ 0.936). Similarly, there
were no signiﬁcant differences in the rates of MACCE, which were 17.6% in the surgical group and 18.2% in the trans-
catheter group (HR: 1.03; 95% CI: 0.78 to 1.36; p ¼ 0.831). The cumulative incidence of cerebrovascular events,
and rehospitalization due to cardiac reasons and acute heart failure was similar in both groups at 1 year.
CONCLUSIONS The results suggest that SAVR and transfemoral TAVR have comparable mortality, MACCE, and rates of
rehospitalization due to cardiac reasons at 1 year. These data need to be conﬁrmed in longer term and dedicated ongoing
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AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
CABG = coronary artery bypass
grafting
MACCE = major adverse
cardiac and cerebrovascular
event(s)
PPM = permanent pacemaker
RCT = randomized controlled
trial(s)
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
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805S evere aortic stenosis (AS) is common; it affects2% to 4% of adults >75 years of age (1).Although surgical aortic valve replacement
(SAVR) is an effective therapy for this condition,
operative mortality and morbidity can be signiﬁcant,
particularly in the elderly. Paradoxically, this means
that the operation can often be prohibitive, and
therefore, inadvisable in the population with the
highest prevalence of aortic valve disease. The intro-
duction of transcatheter aortic valve replacement
(TAVR) offers an effective and less invasive alterna-
tive to SAVR in this extremely complex population.
In 2007, Conformité Européenne mark approval was
granted to both the Edwards SAPIEN (Edwards Life-
Sciences, Irvine, California) and Medtronic CoreValve
(Medtronic, Minneapolis, Minnesota) prostheses;
approval since then has been extended to many
more transcatheter valves. There now exists a consid-
erable body of clinical, quality-of-life, and economic
evidence from registries and from 2 randomized trials
supporting a role for TAVR as an alternative to open
surgery in high-risk patients with severe AS (2–7).
Reﬂecting this evidence, current guidelines recom-
mend performing TAVR in patients who are consid-
ered inoperable or who are at high risk for SAVR (8).SEE PAGE 813Recent observations suggest that European centers
adopting TAVR are selecting patients at lower surgical
risk than recommended by current international
guidelines (8,9). Nevertheless, there is still a paucity
of prospective and controlled data that report on the
comparative effectiveness of TAVR versus SAVR in a
real-world setting (10–13).
The OBSERVANT (Observational Study of Effec-
tiveness of SAVR–TAVI Procedures for Severe Aortic
Stenosis Treatment) trial is an Italian observational
outcome study for the comparative effectiveness of
SAVR–TAVRprocedures for the treatment of severe AS.
Preliminary data that showed 30-day outcomes from
the OBSERVANT study on 266 matched patients were
previously reported (10). The present analysis aims to
describe 1-year clinical outcomes of a large series of
propensity-matched patients from a real-world setting
who underwent transfemoral TAVR and SAVR.
METHODS
STUDY DESIGN AND PATIENT POPULATION. Patient
eligibility criteria, study design and data collection
modalities have been previously described (10).
Brieﬂy, OBSERVANT was a national observational,
prospective, multicenter cohort study that enrolled
consecutive AS patients who underwent TAVR orSAVR at 93 Italian centers (34 hemodynamic
centers and 59 cardiac surgery centers) be-
tween December 2010 and June 2012, and was
run by the Italian National Health Institution
in cooperation with the Italian Ministry of
Health, the National Agency for Regional
Health Services, Italian Regions, and Italian
scientiﬁc societies and federations repre-
senting Italian professionals involved in the
management of AS. Hospitals invited to
participate were those where a procedural
(SAVR and/or TAVR) treatment could
be offered to AS patients (Online Appendix
for the complete list of executive working
group members, participating centers, and
investigators).
The study protocol complies with the Declaration
of Helsinki and has been approved by the Local Ethics
Committee (ASL 2 Melegnano) of the coordinating
Institution (Policlinico San Donato). All patients gave
an informed consent to the scientiﬁc treatment of
their data on an anonymous form.
For the purposes of the present analysis, patients
who underwent an associated procedure or a trans-
aortic and/or transapical TAVR and patients who
reported having a porcelain aorta, hostile thorax,
and those who underwent combined coronary artery
bypass grafting (CABG) or percutaneous coronary
intervention were excluded.
ENDPOINTS AND FOLLOW-UP. The primary end-
points of this analysis were death from any cause, and
major adverse cardiac and cerebrovascular events
(MACCE) at 1 year. MACCE were deﬁned as the com-
posite of death from any cause, stroke, myocardial
infarction, percutaneous coronary intervention and
CABG. Pre-speciﬁed secondary endpoints included
cerebrovascular accidents, acute myocardial infarc-
tion, repeat hospitalization due to cardiac reasons,
and acute heart failure.
The incidence of some selected periprocedural
complications (acute kidney injury, vascular com-
plications, high-degree conduction disturbances
requiring permanent pacemaker [PPM] implantation,
and requirement for blood transfusions) was also con-
sidered. Echocardiographic criteria post-procedure
(prosthesis performance and paravalvular regurgita-
tion) were deﬁned according to the Valve Academic
Research Consortium deﬁnitions (14). The endpoint
deﬁnitions are reported in the Online Appendix.
An administrative follow-up has been set up for
each enrolled patient through a record linkage with
the National Hospital Discharged Records (HDR)
database (for in-hospital events) and with the Tax
Registry Information System (TRIS) (for information
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806on life status). This approach guarantees a very low
percentage of patients lost to follow-up.
DATA QUALITY ASSESSMENT. Speciﬁc quality assess-
ment activities have been arranged to evaluate the
reliability of the OBSERVANT database. In particular,
independent observers, following speciﬁc standard
operating procedures, monitored the participating
hospitals to assess the completeness of the enrolled
cohort and to compare the collected data to those
reported in the original clinical charts.
STATISTICAL ANALYSIS. The data are shown strati-
ﬁed by procedure (SAVR and/or transfemoral TAVR).
Continuous variables are presented as mean  SD, and
are compared using Student t test for the descriptive
analysis. Categorical variables are presented as counts
and percentages, and are compared with the chi-
square test or Fisher exact test, as appropriate.
Because observational studies do not provide
randomization, the propensity score method was
applied to select 2 groups of patients who underwent
SAVR and TAVR, respectively, and who had similar
baseline characteristics. The propensity score was
developed using logistic regression (15). Adopting a
nonparsimonious approach, all measured potential
confounders were used in the regression procedure.FIGURE 1 Patient Flowchart
7,618 patients enro
5,468 patients inclu
4,077 Surgical aortic valve replacement
Propensity score matchi
650 Surgical aortic valve replacement
*Concomitant surgical and/or percutaneous revascularization and interv
ported the nonconsecutiveness of the enrollment. TAVR ¼ transcatheteThe propensity score includes the following variables:
age; sex; previous percutaneous coronary interven-
tion; previous balloon aortic valvuloplasty; previous
cardiac surgery; diabetes; chronic obstructive pulmo-
nary disease; smoking; previous myocardial in-
farction; peripheral arteriopathy; creatinine; critical
preoperative state; unstable angina; neurological
dysfunction; pulmonary hypertension (systolic pul-
monary arterial pressure >60 mm Hg); chronic liver
disease; active neoplastic disease; New York Heart
Association functional class; frailty score [Geriatric
Status Scale (16)]; left ventricular ejection fraction;
coronary artery disease; urgency status; and mitral
regurgitation. Pairs of TAVR and SAVR patients with
the same probability score (nearest neighbor method;
caliper ¼ 0.2  SD[logitPs]) were matched. To evaluate
the balance between the matched groups, the
following tests were used: Student t test for paired
sample for continuous variables; the McNeimar test
for dichotomous variables; and the Stuart-Maxwell
test for categorical variables. Standardized differ-
ences of baseline variables before and after matching
are shown in Online Figure 1. SAVR and TAVR
periprocedural outcomes in the subgroup of the
matched patients were compared using the same
statistical tests.lled
2,150 patients excluded:
Nonfemoral TAVR 
Combined procedures* 
Porcelain aorta
Hostile thorax
Protocol violation†
ded
1,391 Transfemoral TAVR
ng
650 Transfemoral TAVR
ention on other valves. †Centers in which the monitoring process re-
r aortic valve replacement.
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807With regard to long-term outcomes, hazard ratios
(HRs) for death from any cause, MACCE at 1 year, and
time-to-event curves were calculated using Cox pro-
portional hazard models, taking into account pairing
of data.
Problems related to the linkage keys resulted in
25 pairs of TAVR and SAVR patients who were not
linked with the administrative databases and were
deﬁnitively lost to follow-up. Nevertheless, for the
survival analysis, they were considered censored at
the time of discharge after being hospitalized for the
procedure.
Cumulative incidence functions of stroke, acute
myocardial infarction, repeat hospitalization for
acute heart failure, and repeat hospitalization for
cardiac reasons were estimated using a competing-
risks regression by the method of Fine and Gray.
This method uses a semiparametric regression forTABLE 1 Baseline Clinical Characteristics After PS Matching
SAVR
(n ¼ 650)
TAVR
(n ¼ 650) p Value
Age, yrs 80.3  5.1 80.5  6.2 0.323
Female 387 (59.5) 383 (58.9) 0.822
Smoking history 71 (11.5) 62 (10.1) 0.417
BMI, kg/m2 26.9  4.5 26.5  4.8 0.095
Diabetes mellitus 165 (25.4) 161 (24.8) 0.798
Creatinine, mg/dl 1.2  0.8 1.2  0.7 0.823
Long-term dialysis treatment 3 (0.5) 9 (1.4) 0.083
Albumin, mg/dl 3.7  0.9 3.5  0.8 0.006
Hemoglobin, mg/dl 12.3  1.6 11.7  1.7 <0.001
Previous AMI 75 (11.5) 72 (11.1) 0.795
Unstable angina 18 (2.8) 21 (3.2) 0.622
COPD 141 (21.7) 154 (22.3) 0.790
Oxygen dependency 11 (1.7) 36 (5.6) 0.001
Neurologic dysfunction* 37 (5.7) 38 (5.8) 0.904
Chronic liver disease† 23 (3.5) 19 (2.9) 0.527
Active neoplastic disease 16 (2.5) 17 (2.6) 0.853
Peripheral arteriopathy 126 (19.4) 124 (19.1) 0.886
Pulmonary hypertension 88 (14.6) 88 (14.6) 1.000
Previous cardiac surgery 65 (10.0) 62 (9.5) 0.778
Previous vascular surgery 18 (2.8) 22 (3.4) 0.527
Frailty score, moderate–severe 88 (13.5) 85 (13.1) 0.801
Previous PCI 85 (13.1) 94 (14.5) 0.455
Previous BAV 15 (2.3) 24 (3.7) 0.128
Critical preoperative state 24 (3.7) 17 (2.6) 0.274
NYHA functional class III 318 (48.9) 324 (49.8) 0.790
NYHA functional class IV 70 (10.8) 61 (9.4)
Logistic EuroSCORE 1, % 10.2  9.2 9.5  7.1 0.104
Logistic EuroSCORE 2, % 5.1  6.2 4.9  5.1 0.485
Values are mean  SD or n (%). *Any previous neurological event (cerebrovascular
accident or transient ischemic attack). †Child-Pugh classes B and C.
AMI ¼ acute myocardial infarction; BAV ¼ balloon aortic valvuloplasty; BMI ¼
body mass index; COPD ¼ chronic obstructive pulmonary disease; NYHA ¼ New
York Heart Association; PCI ¼ percutaneous coronary intervention; PS ¼ pro-
pensity score; SAVR ¼ surgical aortic valve replacement; TAVR ¼ transcatheter
aortic valve replacement.survival data in the presence of competing risks,
positing a model for the subhazard function of a
failure event of primary interest. In these analyses,
death was considered a competing event because
patients under observation might have died, making
it impossible for the event of interest to occur. This
competing-risks regression was carried out by the
Stata statistical package (StataCorp, College Station,
Texas) with the stcrreg procedure. All statistical an-
alyses were performed using the Stata statistical
package (version 13, StataCorp).
RESULTS
BASELINE CHARACTERISTICS AND PROCEDURAL
DATA OF THE PRE-MATCHING POPULATION. A total
of 7,618 consecutive patients with severe AS who
underwent SAVR (n ¼ 5,707) or TAVR (n ¼ 1,911) were
enrolled in the OBSERVANT study. In TAVR patients,
transfemoral access was used in 1,564 (81.8%),
transapical access in 259 (13.6%), trans-subclavian
access in 73 (3.8%), and direct aortic access in 15
(0.8%). Patients excluded from the present analysis
are listed in the patient ﬂowchart in Figure 1. A total of
5,468 patients (4,077 SAVR and 1,391 transfemoral
TAVR) formed the pre-matching population, and their
baseline demographic and clinical characteristics are
listed in Online Table 1. The mean logistic EuroSCORE
1 was 4.9  5.5% and 13.6  11.4% in the SAVR
and TAVR groups, respectively (p < 0.001) (Online
Figure 2). The mean logistic EuroSCORE 2 was 2.5 
3.4% in the SAVR group and 6.8  7.2% in the TAVR
group (p < 0.001). Echocardiographic ﬁndings before
intervention of the pre-matching population are lis-
ted in Online Table 2. All TAVR procedures were
performed using the third-generation, self-expanding
CoreValve ReValving System (Medtronic Inc.) (N ¼
839; 60.4%) or the balloon-expandable Edwards
SAPIEN XT (Edwards Lifescience) (N ¼ 549; 39.6%)
under local anesthesia (with or without additional
sedation and/or analgesia) or general anesthesia
and endotracheal intubation, under ﬂuoroscopic
guidance and transesophageal echocardiography, ac-
cording to individual institutional practice, in a
standard cardiac catheterization laboratory or hybrid
room, with surgical backup. The choice of SAVR
technique and type of prosthesis used were left to the
cardiac surgeon’s discretion and individual institu-
tional practice.
PROPENSITY-MATCHED GROUPS. Pat ient populat ion .
From the entire cohort, 650 pairs of patients who
underwent SAVR and transfemoral TAVR with similar
baseline demographic and clinical characteristics
were obtained using the propensity score method
TABLE 2
Left ventr
Left ventr
Mitral reg
Mild
Modera
Severe
Aortic valv
Aortic v
Peak gr
Mean g
Annulus
Values are m
Abbreviat
TABLE 3 Periprocedural Clinical Outcomes of the
Propensity Score-Matched Population
Outcomes
SAVR
(n ¼ 650)
TAVR
(n ¼ 650) p Value
Valve migration — 15 (2.3) —
Stroke 14 (2.2) 8 (1.3) 0.180
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ized differences were <0.10 (Online Figure 1).
The use of the propensity score method generated
a matched population with a mean logistic Euro-
SCORE 1 of 9.8  8.3%, with scores of 10.2  9.2% for
the SAVR group versus 9.5  7.1% for the TAVR
group (p ¼ 0.104). The mean logistic EuroSCORE 2
was 5.1  6.2% for the SAVR group and 4.9  5.1%
for the TAVR group (p ¼ 0.485). The procedure was
performed in an emergency setting in 4.0% of SAVR
patients and 3.1% of TAVR patients (p ¼ 0.339). In the
TAVR group, CoreValves or Edwards SAPIEN XT
valves were implanted in 358 (55.1%) and 274 (44.9%)
patients, respectively. SAVR patients had more pro-
longed hospitalization compared with TAVR patients
(12.6  13.4 days vs. 8.8  8.5 days; p < 0.001).
Acute echocardiographic outcomes. TAVR yielded a
slightly lower mean post-procedural aortic valve
gradient than SAVR (13.6  6.7 mm Hg vs. 10.3  5.6
mm Hg, respectively; p < 0.001). However, TAVR was
associated with a higher incidence of paravalvular
regurgitation, with a higher rate of aortic regurgita-
tion (grade $2) compared with SAVR (2.0% for SAVR
vs. 9.8% for TAVR; p < 0.001).
Cl in i ca l outcomes . In the matched population, in-
hospital mortality during the index admission was
3.4% in SAVR patients and 2.0% in TAVR patients
(p ¼ 0.423). Twenty-four SAVR patients (3.8%) and
20 TAVR patients (3.2%) died at 30 days (p ¼ 0.546).
Major periprocedural adverse events, including acute
renal failure (10.9% vs. 6.1%; p ¼ 0.004) and a higher
requirement for blood transfusion (3.6  3.6 red
blood cells units vs. 2.3  2.2 red blood cells units;
p ¼ 0.002) were more frequently reported in the SAVR
group, whereas major access site complications (0.5%
vs. 7.9%; p < 0.001) and a high-degree atrioventric-
ular block that required PPM implantation (3.6% vs.Echocardiographic Characteristics After PS Matching
SAVR
(n ¼ 650)
TAVR
(n ¼ 650) p Value
icular ejection fraction, % 54.2  11.2 53.6  11.4 0.349
icular ejection fraction #30% 20 (3.1) 16 (2.5) 0.499
urgitation
367 (56.5) 348 (53.5) 0.753
te 138 (21.2) 143 (22.0)
14 (2.2) 16 (2.5)
e pattern
alve area, cm2 0.7  0.2 0.7  0.3 0.097
adient, mm Hg 82.1  23.9 82.7  22.1 0.655
radient, mm Hg 51.1  15.9 51.0  14.5 0.918
diameter, mm 21.3  2.1 22.2  2.2 <0.001
ean  SD or n (%).
ions as in Table 1.15.5%; p < 0.001) were higher in the TAVR group.
There were no differences with respect to cerebro-
vascular accidents (2.2% vs. 1.3%; p ¼ 0.180), acute
myocardial infarction (0.8% vs. 0.5%; p ¼ 0.479),
and cardiac tamponade (3.9% vs. 4.1%; p ¼ 0.886)
between the 2 groups (Table 3).
At 1 year, the rate of death from any cause was
13.8% in the transcatheter group compared with
13.6% in the surgical group (HR: 0.99; 95% conﬁdence
interval [CI]: 0.72 to 1.35; p ¼ 0.936) (Central
Illustration, panel A). Similarly, there were no signif-
icant differences in the rates of MACCE, which were
17.6% in the surgical group compared with 18.2%
in the transcatheter group (HR: 1.03; 95% CI: 0.78
to 1.36; p ¼ 0.831) (Central Illustration, panel B).
The cumulative 1-year incidence of cerebrovascular
events, acute myocardial infarction, and rehospitali-
zation due to cardiac reasons and acute heart failure,
as assessed by the competing risk regression ap-
proach, was similar in both groups (Table 4, Figure 2),
whereas the PPM implantation rate was remarkably
higher in the TAVR group (Table 4).
DISCUSSION
The principal ﬁndings of this study of a propensity-
matched population was that transfemoral TAVR
was comparable to surgical replacement with respect
to 1-year rates of death from any cause, MACCE, and
repeat hospitalization due to cardiac reasons.Acute myocardial infarction 5 (0.8) 3 (0.5) 0.479
Renal failure 64 (10.9) 36 (6.1) 0.004
Cardiac tamponade 25 (3.9) 26 (4.1) 0.886
Permanent pacemaker 23 (3.6) 98 (15.5) <0.001
Major vascular damage 3 (0.5) 48 (7.9) <0.001
Infection
Wound 10 (1.6) 6 (1.0) 0.191
Lung or other organs 24 (3.9) 29 (4.7)
Sepsis 11 (1.8) 4 (0.6)
Emergency PCI 0 (0.0) 6 (0.9) —
Transfusions, no. of units 3.6  3.6 2.3  2.2 0.002
Mean gradient after
procedure, mm Hg
13.6  6.7 10.3  5.6 <0.001
ICU stay, days 3.8  7.7 3.2  4.7 0.077
Hospital stay, days 12.6  1.3 8.8  8.5 <0.001
30-day mortality 24 (3.8) 20 (3.2) 0.546
Values are n (%) or mean  SD.
ICU ¼ intensive care unit; other abbreviations as in Table 1.
CENTRAL ILLUSTRATION TAVR Versus SAVR: Time-to-Event Curves for the Primary Endpoints
Tamburino, C. et al. J Am Coll Cardiol. 2015; 66(7):804–12.
Time-to-event curves are shown for (A) death from any cause and (B) MACCE. The event rates were calculated using Kaplan-Meier methods and compared by the
log-rank test. CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACCE ¼ major adverse cardiac and cerebrovascular event(s); SAVR ¼ surgical aortic valve replacement;
TAVR ¼ transcatheter aortic valve replacement.
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809Despite the availability of head-to-head compari-
sons between TAVR and SAVR in randomized clinical
studies, this observational study represents a useful
support for the comparative effectiveness of these
strategies in a real-world setting, generating results
that are likely to be more generalizable than those
from randomized controlled trials (16).TABLE 4 Clinical Outcomes of the Propensity Score-Matched
Population at 1 Year
Outcomes
SAVR
(n ¼ 650)
TAVR
(n ¼ 650)
p
Value
Death from any cause* 82 (13.6) 83 (13.8) 0.912
Stroke† 29 (4.9) 37 (6.4) 0.243
Acute myocardial Infarction† 18 (3.8) 15 (3.1) 0.442
PCI† 3 (0.6) 10 (1.7) 0.055
CABG† 0 (0.0) 0 (0.0) 1.000
MACCE*‡ 107 (17.6) 110 (18.2) 0.796
Repeat hospitalization for
cardiac reasons†
134 (23.6) 127 (21.9) 0.473
Repeat hospitalization for acute
heart failure†
112 (19.7) 110 (19.0) 0.722
Permanent pacemaker† 43 (7.3) 114 (18.5) <0.001
Values are n (%). *Data are reported as Kaplan-Meier estimates at the speciﬁc time
point and do not equal the number of patients with events divided by the total
number of patients in each treatment group. †Data are reported as competitive risk
estimates at the speciﬁc time point and do not equal the number of patients with
events divided by the total number of patients in each treatment group. ‡MACCE
were deﬁned as the composite of death from any cause, stroke, acute myocardial
infarction, PCI, and CABG.
CABG ¼ coronary artery bypass graft; MACCE ¼ major adverse cardiac and
cardiovascular events; other abbreviations as in Table 1.In this study, the baseline characteristics of the
transcatheter group characterize a population with a
lower risk proﬁle than those usually undergoing such
a procedure (2–7). This observation might suggest
that TAVR is increasingly offered not only to inoper-
able or high-risk patients, as recommended by clinical
practice guidelines, but also to those with few or
relative contraindications to surgery. If so, in view of
the excellent short- and long-term results of SAVR
in low-risk patients and the lack of evidence on
very long-term durability of TAVR, this should be a
worrying trend. However, risk stratiﬁcation of pa-
tients treated with TAVR and enrolled in OBSERVANT
was on the basis of the clinical judgment of local heart
teams, rather than according to speciﬁc criteria, such
as surgical risk score. Both versions of the EuroSCORE
alone did not account for clinical characteristics
that might have increased the level of patient risk
perceived by the local heart teams, such as frailty,
difﬁcult anatomy, or comorbidities not captured by
these 2 pre-procedural risk scores (e.g., end-stage
liver diseases and autoimmune disorders).
The death rates from any cause at 30 days and at
1 year in our propensity-matched population were
similar in the transfemoral TAVR and SAVR groups.
Our results are in line with those reported in the
PARTNER (Placement of Aortic Transcatheter Valve
Trial) Cohort A trial in a high-risk population
(3), whereas they differ from those reported by
FIGURE 2 Time-to-Event Curves for the Other Major Outcomes
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(A) Cumulative incidence of stroke, (B) acute myocardial infarction, (C) repeat hospitalization for acute heart failure, and (D) repeat hospitalization for cardiac reasons. The
event rates were calculated using a competing-risks regression and considering death as competing event. CI ¼ conﬁdence interval; SHR ¼ subdistribution hazard ratio.
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810the CoreValve U.S. trial (4), in which survival at
1 year after TAVR was superior to that after SAVR
(Online Figure 3). Putting the results of OBSERVANT
into the perspective of these 2 RCTs, which compared
SAVR versus TAVR, the following should be consid-
ered. The rate of 1-year death from any cause
after isolated SAVR decreased consistently with
the reduction of the logistic EuroSCORE in these
3 studies, which suggested that mortality after
SAVR was predominantly affected by the coexisting
comorbidities of the patients, rather than the proce-
dure itself. However, although 1-year mortality after
TAVR reported in OBSERVANT was remarkably lower
than that reported in PARTNER A, because of the
result of the reduced patient risk proﬁles and the
integration of newer generation devices, mortality at
1 year was similar in the TAVR cohorts of the
OBSERVANT and the U.S. CoreValve studies (13.1%
vs. 14.2%, respectively), despite the large difference
in risk proﬁles between these 2 populations (meanlogistic EuroSCORE: 17.6% vs. 9.5%). A possible
explanation was that a non-negligible proportion of
both early and late deaths after TAVR might be
attributable to procedure-related sequelae (i.e.,
vascular complications, paravalvular regurgitation),
thus suggesting that a learning curve effect and
improved patient selection for TAVR might have
played an important role in determining this result.
Major procedure-related complications rates, such
as neurological events and myocardial infarction,
were similar in the transcatheter and surgical groups
at 1 year. Compared with PARTNER A, we reported
a lower incidence of stroke in the TAVR group,
which was consistent with data from other recent
TAVR registries (17). This might be related to the
use of ﬁrst-generation devices, which were charac-
terized by higher diameter and minor ﬂexibility in
the PARTNER trial.
Finally, rehospitalization rates due to cardiac rea-
sons and acute heart failure were similar in the surgical
PERSPECTIVES
COMPETENCY IN PATIENT CARE: For patients with AS at low
or intermediate surgical risk on the basis of logistic EuroSCORE
assessment, rates of all-cause mortality, major adverse cardio-
vascular events, and hospitalization for cardiac conditions at 1 year
were similar in those who underwent TAVR versus SAVR.
TRANSLATIONAL OUTLOOK: Further studies are needed to
identify patient characteristics other than high surgical risk
scores that are associated with better long-term outcomes with
TAVR than SAVR.
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811and the transcatheter groups. These data could suggest
substantial equipoise in terms of cost-effectiveness
of the 2 procedures in the low- to intermediate-risk
cohort, although more focused studies are warranted
before deﬁnitive conclusions can be drawn.
STUDY LIMITATIONS. The present study had some
strengths and limitations. First, evaluating the impact
of a speciﬁc treatment using an observational study
could lead to weaker conclusions than using an RCT
because treatment was not randomly assigned and
because of potential residual confounding. However,
it has been argued that a well-conducted observational
cohort study could provide the same level of internal
validity as RCTs (18). Moreover, observational studies
are carried out on real-world populations, and there-
fore, could reach higher levels of external validity
compared with RCTs. In this analysis, to partly
compensate for the baseline imbalance between
groups, we applied a propensity approach that repre-
sented a widely used method for analyzing observa-
tional data (15). The high percentage of TAVR matched
with SAVR procedures (47%) represented an excellent
result for studies using this methodology. Neverthe-
less, residual confounding due to unrecorded risk
factors could not be excluded. A speciﬁc strength of
this study was the use of an administrative follow-up,
which guaranteed an extremely low percentage of
patients lost to follow-up, the independence of
outcome observations, and the possibility of very long-
term follow-up analyses in terms of survival, rehospi-
talizations, and costs related to patient management.
Second, the TAVR intermediate-risk group was retro-
spectively selected using propensity matching with
the SAVR group, with no prespeciﬁed threshold for
patient inclusion. Third, Valve Academic Research
Consortium criteria (14) were not used in this study.
These deﬁnitions are speciﬁcally designed to deﬁne
complications after TAVR; therefore, they might be
misleading and were likely to result in overestimation
of complications after SAVR. Fourth, the lack of a core
laboratory to centrally assess echocardiographic pa-
rameters was another important limitation of this
study. Finally, this analysis referred only to patients
who underwent isolated SAVR and transfemoralTAVR. Whether these results could be applied in pa-
tients undergoing concomitant CABG and/or per-
cutaneous coronary intervention or transapical and
transaortic TAVR remains unknown.
CONCLUSIONS
The results of this study on a large propensity-
matched cohort of real-world patients with severe
AS and at low or intermediate surgical risk suggest
that SAVR and transfemoral TAVR have comparable
rates of mortality, MACCE, and rehospitalization
due to cardiac reasons at 1 year. These data need to
be conﬁrmed in longer term and dedicated ongoing
randomized trials (SURTAVI [Safety and Efﬁcacy
Study of the Medtronic CoreValve System in the
Treatment of Severe, Symptomatic Aortic Stenosis in
Intermediate Risk Subjects Who Need Aortic Valve
Replacement] and PARTNER 2).
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